We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
Read MoreHide Full Article
GE HealthCare (GEHC - Free Report) reported first-quarter 2024 adjusted earnings per share (EPS) of 90 cents, which aligned with the Zacks Consensus Estimate. However, the bottom line improved 5.9% year over year.
GAAP EPS in the quarter was 81 cents, up 97.6% from the year-ago quarter’s level.
Revenue Details
This Zacks Rank #3 (Hold) company reported revenues of $4.7 billion, down 1.3%, on a reported basis from the prior-year quarter’s recorded number and flat, organically. The decrease in sale volumes was partially offset by positive pricing. The top line missed the Zacks Consensus Estimate by 2.3%.
Although the company’s revenues declined in the first quarter, it is expected to improve in the second half of 2024 on the back of a healthy backlog, orders growth, and positive book-to-bill.
However, lower-than-expected revenues coupled with lower volume raised apprehension among investors, leading to a 9.2% decline in GEHC stock in pre-market trading. However, shares of the company have gained 10.1% against the industry’s 17.9% decline in the past year.
Image Source: Zacks Investment Research
Segmental Details
Imaging
Revenues from this segment totaled $2.47 billion, indicating a year-over-year decline of 1%, reportedly. Organically, revenues remained flat.
Segment EBIT was $240 million, up 26% year over year.
Ultrasound
This segment’s revenues totaled $824 million, down 4% year over year, reportedly as well as organically.
Segment EBIT was $182 million, down 12% year over year.
Patient Care Solutions
Revenues from this segment amounted to $747 million, down 4% from the year-ago quarter’s level, reportedly as well as organically.
Segment EBIT was $81 million, down 25% year over year.
Pharmaceutical Diagnostics
Revenues from this segment amounted to $599 million, up 7% from the year-ago quarter’s level. Organically, revenues improved 8%.
Segment EBIT was $178 million, up 15% year over year.
Margins
Net income margin was 8%, up 10 basis points from the prior-year period’s level, primarily due to benefits from productivity and pricing.
Cash flow from operating activities was $419 million compared with $468 million in the year-ago period.
Financial Position
GEHC exited the first quarter with cash, cash equivalents and investments of $2.56 billion compared with $2.5 billion in the prior quarter.
Total assets declined to $32.21 billion from $32.45 billion in the prior quarter.
The company repaid $150 million of debt in the first quarter of 2024.
2024 Guidance
GE HealthCare reaffirmed its earnings and revenue guidance for 2024.
For 2024, the company expects adjusted EPS in the range of $4.20-$4.35, indicating an estimated growth of 7-11%. Revenues are anticipated to improve 4% organically. The Zacks Consensus Estimate for EPS and sales is pegged at $4.30 and $20.34 billion, respectively.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
Some better-ranked stocks in the broader medical space are Align Technologies, Inc. (ALGN - Free Report) , Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, and Ecolab Inc. (ECL - Free Report) .
ALGN, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.4%. ALGN’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 5.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALGN’s shares have gained 2.9% compared with the industry’s 3.9% rise in the past year.
BD, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.4%. BDX’s earnings surpassed estimates in three of the trailing four quarters and broke even once, with the average being 4.6%.
BD has lost 11.1% against the industry’s 4.9% rise in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%.
Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
GE HealthCare (GEHC - Free Report) reported first-quarter 2024 adjusted earnings per share (EPS) of 90 cents, which aligned with the Zacks Consensus Estimate. However, the bottom line improved 5.9% year over year.
GAAP EPS in the quarter was 81 cents, up 97.6% from the year-ago quarter’s level.
Revenue Details
This Zacks Rank #3 (Hold) company reported revenues of $4.7 billion, down 1.3%, on a reported basis from the prior-year quarter’s recorded number and flat, organically. The decrease in sale volumes was partially offset by positive pricing. The top line missed the Zacks Consensus Estimate by 2.3%.
Although the company’s revenues declined in the first quarter, it is expected to improve in the second half of 2024 on the back of a healthy backlog, orders growth, and positive book-to-bill.
However, lower-than-expected revenues coupled with lower volume raised apprehension among investors, leading to a 9.2% decline in GEHC stock in pre-market trading. However, shares of the company have gained 10.1% against the industry’s 17.9% decline in the past year.
Image Source: Zacks Investment Research
Segmental Details
Imaging
Revenues from this segment totaled $2.47 billion, indicating a year-over-year decline of 1%, reportedly. Organically, revenues remained flat.
Segment EBIT was $240 million, up 26% year over year.
Ultrasound
This segment’s revenues totaled $824 million, down 4% year over year, reportedly as well as organically.
Segment EBIT was $182 million, down 12% year over year.
Patient Care Solutions
Revenues from this segment amounted to $747 million, down 4% from the year-ago quarter’s level, reportedly as well as organically.
Segment EBIT was $81 million, down 25% year over year.
Pharmaceutical Diagnostics
Revenues from this segment amounted to $599 million, up 7% from the year-ago quarter’s level. Organically, revenues improved 8%.
Segment EBIT was $178 million, up 15% year over year.
Margins
Net income margin was 8%, up 10 basis points from the prior-year period’s level, primarily due to benefits from productivity and pricing.
Cash flow from operating activities was $419 million compared with $468 million in the year-ago period.
Financial Position
GEHC exited the first quarter with cash, cash equivalents and investments of $2.56 billion compared with $2.5 billion in the prior quarter.
Total assets declined to $32.21 billion from $32.45 billion in the prior quarter.
The company repaid $150 million of debt in the first quarter of 2024.
2024 Guidance
GE HealthCare reaffirmed its earnings and revenue guidance for 2024.
For 2024, the company expects adjusted EPS in the range of $4.20-$4.35, indicating an estimated growth of 7-11%. Revenues are anticipated to improve 4% organically. The Zacks Consensus Estimate for EPS and sales is pegged at $4.30 and $20.34 billion, respectively.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. Quote
Zacks Rank and Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Align Technologies, Inc. (ALGN - Free Report) , Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, and Ecolab Inc. (ECL - Free Report) .
ALGN, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.4%. ALGN’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 5.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALGN’s shares have gained 2.9% compared with the industry’s 3.9% rise in the past year.
BD, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.4%. BDX’s earnings surpassed estimates in three of the trailing four quarters and broke even once, with the average being 4.6%.
BD has lost 11.1% against the industry’s 4.9% rise in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%.
Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year.